TB Drug May Also Target Visceral Leishmaniasis

A drug that has already been approved for treatment of tuberculosis could also be a powerful tool to combat another of the developing world’s major diseases, researchers at the University of Dundee have found. Visceral leishmaniasis is a disease which blights the developing world with 200,000 to 400,000 new cases and 48,000 deaths annually. The vast majority of cases are seen in six countries - Bangladesh, Brazil, Ethiopia, India, South Sudan and Sudan. Researchers have discovered that a drug called delamanid, which was recently approved for the treatment of tuberculosis, can cure a mouse model of visceral leishmaniasis at oral doses that may be achievable in patients.
Source : www.dddmag.com      2016/5/30 10:48

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.